Two new studies show no benefit of Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19.

Study 1: Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet Haematology

Study 2: Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial – The Lancet Haematology

Commentaries:

Antithrombotic prophylaxis for symptomatic outpatients with COVID-19: less is consistently more – The Lancet Haematology

Antithrombotic Prophylaxis No Help in Outpatients With COVID — Two trials show no differences between patients who received enoxaparin vs standard of care – MedPage Today (free registration required)

Commentary on Twitter (thread – click for more)

Early in the pandemic we wondered whether antithrombotic therapy in outpatients with #COVID19 would prevent #thrombosis ❓

Several trials were started globally and the ACTIV-4B trial was previously reported⬇️ https://t.co/Q15WcZwDIA

Now, we publish the OVID and ETHIC trials?

— The Lancet Haematology (@TheLancetHaem) June 30, 2022